GlassScriptPhysician profile
David S Zukoff
NPI 1023089778
$28,372.86
in general payments reported to CMS, 2019-2025
37 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $7,214 · 2021: $5,176 · 2022: $1,584 · 2023: $370 · 2024: $912 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20,729.54 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,916.97 | 2019-2024 | |
| Amgen INC. | $644.10 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $477.89 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $452.38 | 2019-2022 | |
| Esperion Therapeutics, INC. | $408.49 | 2020-2024 | Nexletol, Nexlizet |
| Amarin Pharma, INC. | $400.91 | 2019-2021 | |
| Boston Scientific Corporation | $366.07 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $344.58 | 2019-2024 | Camzyos, Eliquis |
| Biotronik INC. | $334.26 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $315.64 | 2021-2024 | Verquvo |
| Abbott Laboratories | $299.61 | 2020-2024 | Aveir, Accent |
| Pfizer INC. | $177.46 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $159.27 | 2020-2022 | |
| Medtronic Vascular, INC. | $158.89 | 2019-2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiofocus, INC. | $143.88 | 2021 | |
| Novo Nordisk INC | $142.36 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| W. L. Gore & Associates, INC. | $140.42 | 2021-2022 | |
| Vifor Pharma, INC. | $94.17 | 2019-2020 | |
| Philips North America LLC | $61.37 | 2022 | |
| Gilead Sciences, INC. | $59.25 | 2019 | |
| Irhythm Technologies, INC. | $57.18 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $55.50 | 2019-2021 | |
| Lilly USA, LLC | $48.10 | 2024-2025 | Mounjaro, Zepbound |
| Bardy Diagnostics, INC. | $45.08 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $44.29 | 2021-2022 | |
| Lundbeck LLC | $43.68 | 2020 | |
| Cardiovascular Systems INC. | $39.86 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $38.88 | 2019 | |
| Astellas Pharma US INC | $27.42 | 2020 | |
| Akcea Therapeutics, INC. | $26.58 | 2020 | |
| Biosense Webster, INC. | $25.89 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.90 | 2024 | |
| Edwards Lifesciences Corporation | $21.30 | 2022 | |
| Biogen, INC. | $18.31 | 2024 | Skyclarys |
| Portola Pharmaceuticals, LLC | $14.93 | 2019 | |
| Vital Connect, INC | $14.45 | 2025 | Vitalpatch Rtm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Zukoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.